Security
Semnur Pharmaceuticals, Inc. Ordinary Shares · SMNR
SMNROTCCommon stockCurrentCIK 1913577Updated Nov 6, 2026
Name history
Denali Capital Acquisition Corp. · through Sep 23, 2025
SMNR price & chart
Loading TradingView…
OTC:SMNR on TradingView ↗About the company
Semnur is a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur’s product candidate, SP-102 (SEMDEXA™), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica. Semnur is headquartered in Palo Alto, California.
In the news
Scilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities ↗
Recent filings
10-Q filing
10-Q filing
424B3 filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 3.02, 7.01, 9.01
424B3 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 774,000Source | 8,924,547Source | 1,943,000Source | 562,462Source | 52,115,789Source | 1,969,000Source | 9,147,903Source | 51,347,261Source | 1,346,000Source | 9,037,873Source | 50,687,403Source | 86,279,436Source |
| Property, Plant and Equipment, NetUSD | 689,000Source | — | 750,000Source | — | — | 750,000Source | — | — | 750,000Source | — | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 85,000Source | — | 39,000Source | — | — | 103,000Source | — | 1,013Source | 20,000Source | — | 204,464Source | — |
| Assets, CurrentUSD | 85,000Source | 35,428Source | 1,193,000Source | 14,144Source | 43,783Source | 1,219,000Source | 2,736Source | 65,412Source | 596,000Source | 16,868Source | 209,440Source | 907,836Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 15,367,000Source | 9,481,571Source | 31,616,000Source | 11,156,451Source | 9,206,623Source | 27,295,000Source | 10,739,217Source | 8,887,007Source | 22,096,000Source | 10,434,584Source | 8,491,480Source | 4,179,141Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 1,000Source | — | 1,000Source | — | — | 1,000Source | — | — | 1,000Source | — | — | 0Source |
| Common Stock, Value, IssuedUSD | 23,000Source | — | 23,000Source | — | — | 23,000Source | — | — | 23,000Source | — | — | — |
| Additional Paid in CapitalUSD | 255,025,000Source | — | 255,026,000Source | — | — | 255,026,000Source | — | — | 255,026,000Source | — | — | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -269,642,000Source | -9,446,400Source | -284,723,000Source | -11,142,564Source | -9,163,097Source | -280,376,000Source | -10,736,738Source | -8,821,852Source | -275,800,000Source | -10,417,973Source | -8,282,297Source | -3,271,562Source |
| Stockholders' Equity Attributable to ParentUSD | -14,593,000Source | -42,008,000Source | -29,673,000Source | -44,448,000Source | -9,162,840Source | -25,326,000Source | -43,449,000Source | -8,821,595Source | -20,750,000Source | -10,417,716Source | -8,282,040Source | -3,271,305Source |
| Liabilities and EquityUSD | 774,000Source | 8,924,547Source | 1,943,000Source | 562,462Source | 52,115,789Source | 1,969,000Source | 9,147,903Source | 51,347,261Source | 1,346,000Source | 9,037,873Source | 50,687,403Source | 86,279,436Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 10,032,000Source | 6,594,071Source | 10,672,000Source | 8,268,951Source | 6,319,123Source | 10,380,000Source | 7,851,717Source | 5,999,507Source | 10,168,000Source | 7,547,084Source | 5,603,980Source | 1,291,641Source |
| Accounts Payable, CurrentUSD | 4,288,000Source | — | 6,918,000Source | — | — | 6,423,000Source | — | — | 5,912,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,266,000Source | — | 1,647,000Source | — | — | 1,190,000Source | — | — | 739,000Source | — | — | — |
| Dividends PayableUSD | 0Source | — | 0Source | — | — | 0Source | — | — | 0Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,484,000Source | 92,000Source | 142,435,000Source | — | — | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 511,000Source | 0Source | 2,145,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,670,000Source | -399,000Source | -5,867,000Source | -753,296Source | -632,783Source | -426,095Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | 43,425,328Source | 39,711,908Source | -84,150,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | 43,425,328Source | 40,536,908Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 2,753,000Source | 394,000Source | 5,875,000Source | -42,859,628Source | -39,694,408Source | 85,395,842Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | — | — | 819,747Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 85,000Source | 13,000Source | 39,000Source | 55,000Source | 103,000Source | 7,000Source | 20,000Source | 16,868Source | 204,464Source | 819,747Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 140,192,000Source | 152,000Source | 1,295,000Source | 119,000Source | 1,484,000Source | 92,000Source | 142,435,000Source | — | — | — |
| DepreciationUSD | — | — | 0Source | 0Source | — | — | 0Source | 0Source | 0Source | — | — | — |
| Dividends PayableUSD | — | — | 0Source | — | 0Source | — | 0Source | — | 0Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 151,451,000Source | 1,065,000Source | 2,975,000Source | 497,000Source | 3,310,000Source | 478,000Source | 157,870,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | — | 25,188Source | 123,000Source | 0Source | — | 26,974Source | — | 96,242Source | — | — |
| Investment Income, InterestUSD | — | — | — | 197,278Source | — | 18,080Source | — | 78,971Source | — | 1,578,042Source | 3,843,271Source | 1,221,600Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -152,594,000Source | -1,298,000Source | -4,347,000Source | -999,000Source | -4,576,000Source | -665,000Source | -160,416,000Source | -167,306Source | 632,536Source | -419,390Source |
| Operating Costs and ExpensesUSD | — | — | — | 212,951Source | — | 374,857Source | — | 246,600Source | — | 1,649,106Source | 3,173,826Source | — |
| Operating ExpensesUSD | — | — | 152,594,000Source | 1,298,000Source | 4,224,000Source | 999,000Source | 4,576,000Source | 665,000Source | 160,416,000Source | — | — | — |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 825,000Source | — |
| Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -152,594,000Source | -1,298,000Source | -4,224,000Source | -999,000Source | -4,576,000Source | -665,000Source | -160,416,000Source | -1,649,106Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | 0Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -152,594,000Source | -1,298,000Source | -4,347,000Source | -999,000Source | -4,576,000Source | -665,000Source | -160,416,000Source | -167,306Source | 632,536Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.76Source | -0.01Source | -0.02Source | -0.01Source | -0.02Source | -0.01Source | -0.78Source | — | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.76Source | -0.01Source | -0.02Source | -0.01Source | -0.02Source | -0.01Source | -0.78Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 201,686,617Source | 200,000,000Source | 230,209,142Source | 200,000,000Source | 230,209,142Source | 200,000,000Source | 204,784,615Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 201,686,617Source | 200,000,000Source | 230,209,142Source | 200,000,000Source | 230,209,142Source | 200,000,000Source | 204,784,615Source | — | — |
| Interest Expense (non-operating)USD | — | — | — | 25,188Source | 123,000Source | 0Source | — | 26,974Source | — | 96,242Source | — |
| Additional Financial Items | |||||||||||
| General and Administrative ExpenseUSD | — | — | 151,451,000Source | 1,065,000Source | 2,975,000Source | 497,000Source | 3,310,000Source | 478,000Source | 157,870,000Source | — | — |
| Interest ExpenseUSD | — | — | — | — | — | 28,345Source | — | 26,974Source | — | 96,242Source | 36,909Source |
| Investment Income, InterestUSD | — | — | — | 197,278Source | — | 18,080Source | — | 78,971Source | — | 1,578,042Source | 3,843,271Source |
| Operating Costs and ExpensesUSD | — | — | — | 212,951Source | — | 374,857Source | — | 246,600Source | — | 1,649,106Source | 3,173,826Source |
| Operating ExpensesUSD | — | — | 152,594,000Source | 1,298,000Source | 4,224,000Source | 999,000Source | 4,576,000Source | 665,000Source | 160,416,000Source | — | — |
| Other Cost and Expense, OperatingUSD | — | — | — | — | — | 61,214Source | — | 131,693Source | — | 485,144Source | — |
| Other ExpensesUSD | — | — | — | — | — | — | — | — | — | — | 30,000,000Source |
| Research and Development ExpenseUSD | — | — | 1,143,000Source | 233,000Source | 1,249,000Source | 502,000Source | 1,266,000Source | 187,000Source | 2,546,000Source | — | — |
| Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | — | — | — | — | — |
Offerings
Registration 333-290995
Filing attachments
smnr-ex99_1.htm · 8-K · 2026-07-07
EX-99.1 2 smnr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE July 7, 2026 Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex Holding Company, Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP PALO ALTO, CALIFORNIA - July 7, 2026 (GLOBE NEWSWIRE) - Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) (OTC: SMNR), a clinical late-stage specialty pharmaceutical company focused on the developme…
Read attachment ↗